08/10/1999
Investors in Tepnel, the DNA diagnostic systems outfit, have been presented with pre-tax losses of £2.38m at the interim stage to June - in line with company forecasts. In an upbeat statement, the board said that a new DNA purification instrument had provoked a considerable amount of commercial interest since its launch at a US scientific fair in the summer. However, it was unable to impart news of anything concrete in the way of commercial contracts. Turnover at the halfway stage was £174,000.
| Market cap: | £23.9m |
| PE Average: | 29 |
| PE Forecast: | n/a |
| PE Historic: | n/a |
| Share price: | 49.0p |
| AIM | £26.28m |
11.00p
|
0.00p
|
|
| Other company articles: |
| 14/10/2008 |
| 17/12/2007 |
| 05/09/2007 |
| 15/07/2005 |
| 27/03/2002 |
Manage Your Finances
Money, tax and benefits : your official guide.
